Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Biosimilares

Anti-Human TREM-1 Reference Antibody (PY159, RUO) (HV219016)

Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Anti-Human TREM-1 Reference Antibody (PY159, RUO)
Precio(USD):
Especificación:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoHV219016
Reactividad de especiesHuman
AplicacionesELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huéspedHuman
ClonalidadMonoclonal
IsotipoIgG1-kappa
ID de clonPY159
Actividad biológica PY159 induceS signaling, upregulate monocyte activation markers, and stimulate proinflammatory cytokine production in human whole blood and dissociated primary tumor cells in vitro [3].
Sistema de expresión Mammalian cells
Objetivo TREM1, Triggering receptor expressed on monocytes 1, Triggering receptor expressed on myeloid cells 1, TREM-1, CD354
Nivel de endotoxinas < 10 EU/mg
Pureza >95% purity as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso Q9NP99
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativosPY159
Fondo

Triggering receptor expressed on myeloid cells 1 (CD354/TREM1) is a ~26 kDa protein. Cell surface receptor that plays important roles in innate and adaptive immunity by amplifying inflammatory responses. Upon activation by various ligands such as PGLYRP1, HMGB1 or HSP70, multimerizes and forms a complex with transmembrane adapter TYROBP/DAP12. In turn, initiates a SYK-mediated cascade of tyrosine phosphorylation, activating multiple downstream mediators such as BTK, MAPK1, MAPK3 or phospholipase C-gamma. This cascade promotes the neutrophil- and macrophage-mediated release of pro-inflammatory cytokines and/or chemokines, as well as their migration and thereby amplifies inflammatory responses that are triggered by bacterial and fungal infections. By also promoting the amplification of inflammatory signals that are initially triggered by Toll-like receptor (TLR) and NOD-like receptor engagement, plays a major role in the pathophysiology of acute and chronic inflammatory diseases of different etiologies including septic shock and atherosclerosis.

1. Bouchon, A. et al. (2000) Journal of immunology (Baltimore, Md. : 1950) 164, 4991-5. PMID: 10799849
2. Arts, RJ. et al. (2011) European cytokine network 22, 11-4. PMID: 21393102
3. El Mezayen, R. et al. (2007) Immunology letters 111, 36-44. PMID: 17568691
4. Read, CB. et al. (2015) Journal of immunology (Baltimore, Md. : 1950) 194, 1417-21. PMID: 25595774
5. Carrasco, K. et al. (2019) Cellular & molecular immunology 16, 460-472. PMID: 29568119
6. Radaev, S. et al. (2003) Structure (London, England : 1993) 11, 1527-35. PMID: 14656437
7. Ormsby, T. et al. (2011) Blood 118, 936-45. PMID: 21659545
8. Fortin, CF. et al. (2007) International immunology 19, 41-50. PMID: 17098818
9. Bouchon, A. et al. (2001) Nature 410, 1103-7. PMID: 11323674
Referencias 1. Oladapo Yeku, et al. Evaluation of myeloid targeting agents, PY159 and PY314, in two dose expansion phase Ib trials in platinum-resistant ovarian cancer. December 2023. Immuno-Oncology Technology. [HV219016]
2. Yeku OO, et al. Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer. 2025;13(3):e010959. Published 2025 Mar 13. [HV219016]
3. Nadine Jahchan, et al. Tuning the tumor microenvironment by reprogramming TREM1+ myeloid cells to unleash anti-tumor immunity in solid tumors. Journal for ImmunoTherapy of Cancer. November 2021. 9(Suppl 3):A900-A900 [HV219016]
4. Ira Seth Winer, et al. A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1). J Clin Oncol 41, 2523-2523(2023). View More [HV219016]
Nota For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG1 (LALAPG) Recombinant Isotype Control Antibody (HyHEL-10) (HP688307)
Imágenes
  • Anti-Human TREM-1 Reference Antibody (PY159, RUO)

    Bioactivity

    Detects Human CD354/TREM1 in indirect ELISAs.

  • Anti-Human TREM-1 Reference Antibody (PY159, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Anti-Human CD354/TREM1 (PY159).

  • Anti-Human TREM-1 Reference Antibody (PY159, RUO)

    Western blot

    Western blot analysis was performed using anti-CD354/TREM1 monoclonal antibody at 1μg/ml on various samples.
    Lane 1: recombinant human CD354/TREM1 (Catalog No: HV219012), 50ng
    Lane 2: recombinant human CD354/TREM1 (Catalog No: HV219012), 30ng

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores